Cellular transplantation

New horizons in the surgical management of heart failure

N. Al Attar, A. B. Razak, M. Scorsin

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

End-stage heart failure results from the irreversible destruction of cardiomyocytes, which do not have the capacity to regenerate. Transplantation of myogenic cells into the damaged myocardium is an emerging therapeutic alternative in the management of this major public health problem. Experimental and clinical data suggest that cellular transplantation could improve ventricular function in ischaemic or dilated cardiomyopathies. Implantation of allogeneic and autologous cell types has been applied to induce cardiac myogenesis and, recently, other cell types have been tested for the induction of myocardial angiogenesis. The results of cellular transplantation are encouraging although the role of therapeutic angiogenesis remains to be clarified and the full potential of cellular transplantation to be determined.

Original languageEnglish
Pages (from-to)749-752
Number of pages4
JournalJournal of the Royal College of Surgeons of Edinburgh
Volume47
Issue number6
Publication statusPublished - 01-12-2002
Externally publishedYes

Fingerprint

Heart Failure
Transplantation
Ventricular Function
Muscle Development
Cell Transplantation
Dilated Cardiomyopathy
Cardiac Myocytes
Myocardium
Public Health
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

@article{12322f45b6454035bf355913af2b1a58,
title = "Cellular transplantation: New horizons in the surgical management of heart failure",
abstract = "End-stage heart failure results from the irreversible destruction of cardiomyocytes, which do not have the capacity to regenerate. Transplantation of myogenic cells into the damaged myocardium is an emerging therapeutic alternative in the management of this major public health problem. Experimental and clinical data suggest that cellular transplantation could improve ventricular function in ischaemic or dilated cardiomyopathies. Implantation of allogeneic and autologous cell types has been applied to induce cardiac myogenesis and, recently, other cell types have been tested for the induction of myocardial angiogenesis. The results of cellular transplantation are encouraging although the role of therapeutic angiogenesis remains to be clarified and the full potential of cellular transplantation to be determined.",
author = "{Al Attar}, N. and Razak, {A. B.} and M. Scorsin",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "47",
pages = "749--752",
journal = "Journal of the Royal College of Surgeons of Edinburgh",
issn = "0035-8835",
publisher = "Edinburgh University Press",
number = "6",

}

Cellular transplantation : New horizons in the surgical management of heart failure. / Al Attar, N.; Razak, A. B.; Scorsin, M.

In: Journal of the Royal College of Surgeons of Edinburgh, Vol. 47, No. 6, 01.12.2002, p. 749-752.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cellular transplantation

T2 - New horizons in the surgical management of heart failure

AU - Al Attar, N.

AU - Razak, A. B.

AU - Scorsin, M.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - End-stage heart failure results from the irreversible destruction of cardiomyocytes, which do not have the capacity to regenerate. Transplantation of myogenic cells into the damaged myocardium is an emerging therapeutic alternative in the management of this major public health problem. Experimental and clinical data suggest that cellular transplantation could improve ventricular function in ischaemic or dilated cardiomyopathies. Implantation of allogeneic and autologous cell types has been applied to induce cardiac myogenesis and, recently, other cell types have been tested for the induction of myocardial angiogenesis. The results of cellular transplantation are encouraging although the role of therapeutic angiogenesis remains to be clarified and the full potential of cellular transplantation to be determined.

AB - End-stage heart failure results from the irreversible destruction of cardiomyocytes, which do not have the capacity to regenerate. Transplantation of myogenic cells into the damaged myocardium is an emerging therapeutic alternative in the management of this major public health problem. Experimental and clinical data suggest that cellular transplantation could improve ventricular function in ischaemic or dilated cardiomyopathies. Implantation of allogeneic and autologous cell types has been applied to induce cardiac myogenesis and, recently, other cell types have been tested for the induction of myocardial angiogenesis. The results of cellular transplantation are encouraging although the role of therapeutic angiogenesis remains to be clarified and the full potential of cellular transplantation to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0036963287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036963287&partnerID=8YFLogxK

M3 - Review article

VL - 47

SP - 749

EP - 752

JO - Journal of the Royal College of Surgeons of Edinburgh

JF - Journal of the Royal College of Surgeons of Edinburgh

SN - 0035-8835

IS - 6

ER -